Stem cell

Results: 5459



#Item
91

Bridging the Gap Peiman Hematti illuminates the challenges of translational research in cellular therapies by Josh Knackert UW-Madison’s Stem Cell and Regenerative Medicine

Add to Reading List

Source URL: stemcells.wisc.edu

- Date: 2016-11-09 13:27:22
    92

    ASX ANNOUNCEMENT 7 April 2016 Cynata Reports Compelling Results from Pre-clinical Stem Cell Study in Graft-versus-Host Disease (GvHD)

    Add to Reading List

    Source URL: cynata.com

    - Date: 2016-04-06 19:42:39
      93

      A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R,

      Add to Reading List

      Source URL: s3.amazonaws.com

      - Date: 2014-09-25 16:14:56
        94

        Microsoft Word - MSOB#063 Spinning Stem Cell Fairy Tales.docx

        Add to Reading List

        Source URL: www.ncbcenter.org

        - Date: 2016-07-29 15:38:02
          95

          Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

          Add to Reading List

          Source URL: posters.omed.s3.amazonaws.com

          - Date: 2015-06-12 10:36:45
            96

            Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain

            Add to Reading List

            Source URL: posters.omed.s3.amazonaws.com

            - Date: 2015-11-04 11:34:18
              97

              CMR[B] iPSC PLATFORM The iPSC Platform of the CMR[B] is integrated by the Stem Cell Bank and the Core Facility of this center. The aim of the platform is to offer orientation, support and technical help to the whole scie

              Add to Reading List

              Source URL: www.cmrb.eu

              - Date: 2016-11-25 08:49:58
                98

                A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)

                Add to Reading List

                Source URL: posters.omed.s3.amazonaws.com

                - Date: 2016-01-22 10:42:40
                  99

                  A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM

                  Add to Reading List

                  Source URL: s3.amazonaws.com

                  - Date: 2014-09-25 16:14:56
                    100

                    Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency Wan-Ching Yen, Marcus M. Fischer, Gretchen Argast, Breanna Wallace, Min Wan

                    Add to Reading List

                    Source URL: posters.omed.s3.amazonaws.com

                    - Date: 2015-11-04 11:34:26
                      UPDATE